FDA Panel Calls For More Studies Of Mini-Slings For Urinary Incontinence
This article was originally published in The Gray Sheet
Executive Summary
FDA’s Obstetrics and Gynecology Device panel recommends second-generation mini-slings to treat stress urinary incontinence be subject to 510(k) pre-market clinical trial requirements and additional post-market data collection mandates.
You may also be interested in...
Surgical Mesh And Sling Devices Must Undergo Post-Market Studies
FDA sends post-market study orders to 33 manufacturers of urogynecologic surgical mesh used for pelvic organ prolapse and to seven makers of single-incision mini-slings used for stress urinary incontinence.
FDA Panel: Transvaginal Mesh For Prolapse Should Be Class III
Current and future surgical mesh devices for pelvic organ prolapse repair would require PMA submissions under a recommendation last week by FDA’s Obstetrics and Gynecology Devices panel.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.